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Abstract 11 
 12 
In the evaluation of the oral bioavailability of a mycotoxin, the first step is the determination 13 
of its bioaccessibility, i.e., the percentage of mycotoxin released from the food matrix during 14 
digestion in the gastrointestinal (GI) tract that could be absorbed through the intestinal 15 
epithelium. As a first approximation to the problem, different in vitro digestion models have 16 
been recently used for bioaccessibility calculation, thereby avoiding the use of more complex 17 
cell culture techniques or the use of animals in expensive in vivo experiments. 18 
In vitro methods offer an appealing alternative to human and animal studies. They usually are 19 
rapid, simple and reasonably low in cost, and can be used to perform simplified experiments 20 
under uniform and well-controlled conditions, providing insights not achievable in whole 21 
animal studies. The available in vitro methods for GI simulation differ in the design of the 22 
system, the composition of the physiological juices assayed, as well as in the use or not of 23 
intestinal microbiota. There are models that only simulate the upper part of the GI tract 24 
(mouth-stomach-small intestine), whereas other methods include the large intestine, so that 25 
the model chosen could have some influence on the bioaccessibility data obtained. 26 
Bioaccessibility depends on the food matrix, as well as on the contamination level and the 27 
way the food/feed is contaminated (spiked or naturally). 28 
This review focuses on the currently available data regarding the in vitro digestion models for 29 
the study of the bioaccessibility or absorption of mycotoxins, detailing the characteristics of 30 
each digestion step and the importance of the physiological juices employed during digestion. 31 
The effect that different factors play on the mycotoxin release from food matrix in the GI tract 32 
is also considered, and existing data on bioaccessibility of the main mycotoxins are given.  33 
 34 
Keywords: masked mycotoxins, bioaccessibility, gastrointestinal simulation, intestinal 35 
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 37 
1. Introduction 38 
 39 
Mycotoxins are a wide group of fungal secondary metabolites that exert multiple toxic effects 40 
on humans and animals. Some mycotoxins can cause autoimmune illnesses, have allergenic 41 
properties, and some of them are teratogenic, carcinogenic, mutagenic, nephrotoxic or 42 
estrogenic (CAST, 2003). Although hundreds of mycotoxins exist, the most important for 43 
public health are aflatoxins (AFs, aflatoxins AFB1, AFB2, AFG1 and AFG2 being the main 44 
ones), ochratoxin A (OTA), patulin (PAT), fumonisins (FBs) zearalenone (ZEA), and the 45 
trichothecene group, among them deoxynivalenol (DON), nivalenol (NIV), T-2 and HT-2 46 
toxins being the most important. Recently, other mycotoxins - the so-called emerging 47 
mycotoxins, such as fusaproliferin, beauvericin (BEA), enniatins (ENs), moniliformin and the 48 
Alternaria toxins - are attracting the attention of researchers. 49 
The major mycotoxin-producing fungal genera are Aspergillus, Penicillium, Fusarium and 1 
Alternaria (Moss, 1992; Sweeney and Dobson, 1998). The growth of mycotoxigenic strains 2 
of these fungi on crops, either in the field or during storage, could lead to the accumulation of 3 
mycotoxins in a great variety of foods. Besides, the metabolism of ingested mycotoxins could 4 
result in modified mycotoxins, as happens when aflatoxin B1 (AFB1) is converted by 5 
hydroxylation to aflatoxin M1 (AFM1), mycotoxin mainly present in milk as a result of AFB1 6 
metabolism in cow and other mammals (Prandini et al., 2009). 7 
Natural occurrence of mycotoxins in food has been broadly documented. Thus, mycotoxins 8 
have been widely detected in food of vegetal origin, mainly in cereals (barley, wheat, corn, 9 
oat, etc.) and their by-products (Marín et al., 2012; Rodrigues and Naehrer, 2012), as well as 10 
in nuts, dried fruits, spices, cocoa, coffee, beer, wine, and fruits, particularly apples (Bellí et 11 
al., 2002; Fernández-Cruz et al., 2010; Molyneux et al., 2007; Placinta et al. 1999; Santos et 12 
al., 2010; Turcotte et al., 2011). Mycotoxins also enter the human food chain via meat or 13 
other animal products such as eggs, milk and cheese as a result of contaminated livestock feed 14 
(Chen et al., 2012; Meyer et al., 2003). 15 
This huge variety of food matrices in which mycotoxins occur can have a very significant 16 
effect on the bioavailability of mycotoxins, as complex and diverse reactions can occur 17 
between mycotoxin and the food matrix, which could interfere in the way these toxins are 18 
absorbed through the intestinal tract. 19 
On the other hand, in the last years many structurally related compounds generated by plant 20 
metabolism or by food processing have been described in mycotoxin-contaminated 21 
commodities, which can co-exist together with the native toxins. These mycotoxin derivatives 22 
(named conjugated or “masked” mycotoxins) may have a very different chemical behaviour, 23 
thus they can easily escape routine analyses. Nevertheless, these forms could be hydrolysed to 24 
their precursors in the digestive tracts of animals or could exert toxic effects comparable to 25 
those imputable to free mycotoxins (De Saeger and van Egmond, 2012; Galaverna et al., 26 
2009). This can make in some occasions very difficult to establish a clear relationship 27 
between the amount of ingested toxin and the toxic effects observed, and expected, for a 28 
given amount of mycotoxin. All these facts could help to explain the so-called “fumonisin 29 
paradox” (i.e. the fact that apparently low contaminated commodities induce severe toxic 30 
effects in animals), whereby the oral bioaccessibility of this mycotoxin could be affected by 31 
different factors, one of them the uptake of fumonisin B1 (FB1) strongly conjugated to the 32 
food matrix or FB1 derivatives with higher bioavailabilities (Shier, 2000). This could also 33 
happen with other mycotoxins. 34 
So, knowing the amount of mycotoxin ingested may not be enough for exposure assessment. 35 
Knowing the amount of toxin that becomes available for absorption through the intestinal 36 
epithelium (which will be the measure of its bioaccessibility) is also required. Different 37 
factors, as pH changes, enzymatic activities, etc., play an important role during the 38 
gastrointestinal transit of mycotoxins and thus affect bioaccessibility. 39 
To determine the bioaccessibility of mycotoxins (or in same cases, the absorption), and as a 40 
first approximation to the problem, different in vitro digestion models have been used, 41 
avoiding the use of more complex cell cultures or the ethically questionable use of animals in 42 
in vivo experiments. 43 
This review focuses on the currently available data regarding the in vitro digestion models for 44 
the study of the bioaccessibility of mycotoxins, detailing the characteristics of each digestion 45 
step and the importance of the physiological juices employed during digestion. The effect that 46 
different factors play on the mycotoxin release from food matrix in the GI tract is also 47 
considered, and existing data on bioaccessibility of the main mycotoxins are given.  48 
 49 
2. Bioaccessibility and bioavailability 50 
 1 
The amount of mycotoxin consumed via food does not always reflect the amount of this 2 
compound that is available to exert its toxic action in a target organ of the body, as only a part 3 
of the ingested compound will be bioavailable. Thus the oral bioavailability (F) of a 4 
mycotoxin has been defined as the fraction of an orally ingested mycotoxin, in a certain food 5 
matrix, that finally reaches the systemic circulation and is distributed throughout the entire 6 
body to exert its toxic effect (Versantvoort, 2004). This definition assumes that toxicity is 7 
exerted by the parent compound and not by formed metabolites. 8 
In fact, the oral bioavailability comprises three different and sequential processes (Brandon et 9 
al., 2006): 10 
a) the release of the mycotoxin from the food matrix during digestion in the GI tract. In this 11 
step we are measuring the bioaccessible mycotoxin (FB). 12 
b) the absorption of the bioaccessible mycotoxin through the intestinal epithelial cells of the 13 
GI tract (FA), being transported to the blood (or lymph) stream. 14 
c) the metabolism of the mycotoxin previous to systemic circulation (i.e., the 15 
biotransformation and excretion by the intestinal epithelium or the liver), the so-called first 16 
pass effect (FM). 17 
So, the equation that defines the bioavailable fraction of an ingested mycotoxin, that is, the 18 
fraction that reaches the systemic circulation, is defined by: 19 
 20 
F = FB x FA x FM   (1) 21 
 22 
Bioaccessibility (B) has become important because it represents the amount of the mycotoxin 23 
that can reach the blood after intestinal absorption. It is worth to mention that bioaccessibility 24 
has been calculated only in in vitro systems. This concept is only applicable to oral exposure. 25 
Other routes of exposure do not depend on the process described above. Bioaccessibility is 26 
given in percentages and calculated with the following formula: 27 
 28 
B (%) = [mycotoxinchyme] after GI digestion / [mycotoxinfood matrix] before GI digestion   (2) 29 
 30 
Physiologically speaking, bioaccessibility refers to the amount of toxin that is liberated from 31 
the food matrix in the stomach and is available for absorption in the small intestine 32 
(Peijnenburg and Jager, 2003; Ruby et al., 1996). Bioaccessibility (some times called 33 
digestibility) involves all the events that occur before intestinal and hepatic presystemic 34 
metabolism, and that take place during the digestion of food until the macronutrients and 35 
micronutrients can be assimilated into the cells of the intestinal epithelium (Fernandez-García 36 
et al., 2009), and can be considered as an indicator for the maximal oral bioavailability of the 37 
toxin, which can be used for realistic worst case risk assessment of the toxin in a consumer 38 
product (Brandon et al., 2006). 39 
For a mycotoxin administered in solution, as it is with drinking water, the bioaccessibility of 40 
the toxin is assumed to be 100%. The toxin does not need to be mobilized from the matrix as 41 
it is already in solution and, thereby, available for absorption in the intestine. After ingestion 42 
of other matrices such as feed or food, the toxin may be partially or totally released from their 43 
matrix during digestion in the GI tract. Only the bioaccessible fraction is available for 44 
transport across the intestinal epithelium and can contribute to the internal exposure 45 
(Versantvoort et al., 2004). 46 
The food matrix mainly affects the bioaccessibility, whereas absorption and metabolism 47 
depend more on the toxin specific properties and on the animal physiology and, therefore, the 48 
food matrix is expected to have less influence on theses processes (Brandon et al., 2006). 49 
Thus the bioaccessibility of a given mycotoxin can differ according to the considered food, as 50 
has recently been demonstrated in the case of the bioaccessibilities of DON in different types 1 
of Italian pasta (Raiola et al., 2012b), of BEA in wheat crispy breads with different fiber 2 
concentrations (Meca et al., 2012b) and of PAT in different apple products (Raiola et al., 3 
2012a). 4 
 5 
3. In vitro digestion models 6 
 7 
As described before, the bioaccessibility depends on the mycotoxin and the food matrix 8 
considered. This implies that for health risk assessment of the more important mycotoxin-9 
contaminated foods, it would be convenient to obtain food-specific results of oral 10 
bioavailability in order to better adjust the legal limits of different food groups. Thus, in vitro 11 
digestion models based on human or animal physiology have been developed, not only for 12 
mycotoxins, but also for other areas of application. Most researches have been devoted to 13 
investigation of bioaccessibility of food components and contaminants, but also of  toxics on 14 
soils (Avantaggiato et al., 2003; Boisen and Eggum, 1991; Brandon et al., 2006; Döll et al., 15 
2004; Dominy et al., 2004; Garret et al., 1999; Gil-Izquierdo et al., 2002; Larson et al., 1997; 16 
Miller et al., 1981; Minekus, 2005; Minekus et al., 1999, Oomen et al., 2003; Ortega et al., 17 
2009; Ruby et al., 1999; Savoie, 1994; Versantvoort et al., 2004, 2005).  18 
Most of the in vitro digestion models simulate, in a simplified manner, the digestion processes 19 
in mouth, stomach, and small intestine, often obviating some physiological processes that 20 
occur during digestion, such as peristalsis or the existence of intestinal microbiota. 21 
Digestion is a well known process in which the breaking down of food into smaller 22 
components that can be absorbed by the bloodstream and distributed throughout the body 23 
takes place. Briefly, in humans, and in general in the monogastric animals, digestion is a 24 
sequential process that begins with a mechanical and chemical digestion in the mouth, where 25 
food is chewed and mixed with saliva (rich in amylases) and where many polysaccharides are 26 
breaking down. Then, the stomach continues smashing the food and breaking food 27 
constituents mechanically and chemically with the aid of pepsine and some gastric lipases; 28 
mainly protein and peptide degradation takes place, although some lipolysis also occurs 29 
(Forte, 1996). In the small intestine, where absorption of nutrients is mainly conducted, the 30 
presence of lipids in the duodenum stimulates the secretion of bile salts, phosphatidylcholine, 31 
and cholesterol from the gall bladder and pancreatic fluids (containing pancreatic 32 
lipase/colipase, etc.) from the pancreas. Water and minerals are reabsorbed back into the 33 
blood in the colon (large intestine), together with some vitamins, such as biotin and vitamin K 34 
produced by bacteria (Conigrave and Young, 1996). 35 
The in vitro digestion models try to mimic this layout, especially in the first three 36 
compartments of the GI tract (because mycotoxin absorption takes place mainly in the small 37 
intestine). Main parameters to control are temperature (although if simulates human GI tract 38 
all reactions are carried out at 37 ºC), time in each compartment, pH changes, ionic strength, 39 
gastric/intestinal juice composition and enzymatic activities.  40 
The main features that are requested to an optimum in vitro dynamic digestion model are 41 
(Minekus, 2005; Versantvoort et al., 2004;):  42 
1) The model must be similar and representative of the physiological processes in the human 43 
body (or in the considered animal).  44 
2) Digestion must be a dynamic process which helps to food disintegration and absorption. 45 
Biochemical reactions, flow (hydrodynamics) and mechanical forces must be in accordance 46 
with the kinetics of digestion. The rate of release (emptying) should be controlled for a 47 
quick or prolonged release. 48 
3) The system should allow simulating fasted or fed conditions. 49 
4) The model should include anaerobic conditions and presence of typical GI microbiota. 50 
5) The methodology should be easy and applicable, robust and reproducible.  1 
 2 
Most of the designed models attempt to fulfill with the first four requirements, the latter being 3 
the more difficult to achieve due to methodological complications related to the anaerobic 4 
assay conditions. 5 
With regard to the type of models used, most models are static GI models which simulate the 6 
transit through the digestive tract by sequential (compartmentalized) exposure of the food to 7 
simulated mouth, gastric and small intestinal conditions. These models are a good first 8 
approximation to the problem, as they are of easy performance, and generally allow rapid 9 
processing of a large number of samples, but represent in a lesser extent the GI physiological 10 
reality. 11 
On the other hand, dynamic GI models mimic the gradual transit of ingested compounds 12 
through the simulated compartments of the GI tract, giving a more realistic simulation. In 13 
these models, successive physiological conditions in the stomach and segments of the 14 
intestines of humans and animals are closely simulated. Digestion products and other small 15 
molecules are absorbed from the different intestinal compartments by dialysis. These models 16 
usually take into account factors as gastric emptying patterns, GI transit times in combination 17 
with changing pH values, variable concentration of electrolytes, enzymes and bile salts, 18 
absorption of water and, in some cases, microbial activity during passage of the food through 19 
the entire GI tract (Zeijdner et al., 2004). 20 
There are many biological conditions which differ from in vitro and in vivo systems. The best 21 
approximation to the composition of digestive juices ensures better mimicked digestion in the 22 
GI tract and the results may be approximate to those observed in vivo. However, in some 23 
cases the results do not agree with those observed in in vivo, as will be seen below for FB1 in 24 
vitro simulation. 25 
 26 
3.1. Main physiological components of the in vitro models. 27 
 28 
3.1.1. Saliva. 29 
 30 
Digestion is a physiological process that starts in the mouth with a mechanic action during 31 
which salivary fluids initiate the hydrolytic processes, the central nervous system is 32 
stimulated and the cephalic phase of digestion is initiated. Salivary fluid is an exocrine 33 
secretion consisting of approximately 99% water, containing a variety of electrolytes (sodium, 34 
potassium, calcium, chloride, magnesium, bicarbonate, phosphate) and proteins, including 35 
enzymes (mainly amylases and, in a minor extent, lipases), immunoglobulins and other 36 
antimicrobial factors (lysozyme, peroxidase systems, lactoferrin, histatins and agglutinins), 37 
hormones, mucosal glycoproteins, traces of albumin and some polypeptides and oligopeptides 38 
of importance to oral health. There are also glucose and nitrogenous products, such as urea 39 
and ammonia (Rantonen, 2003). 40 
Saliva production is stimulated by visual and olfactory stimuli, sour taste, chewing and the 41 
presence of food particles in the mouth. Composition of saliva depends on the flow rate: at 42 
higher flow rates, sodium, calcium, chloride, bicarbonate and amylases increase, whilst 43 
phosphate concentrations and mucin decrease, and the potassium concentration show little 44 
change (Versantvoort et al., 2004).  45 
The salivary α-amylase, which acts as an endoglycosidase, hydrolyzes starch and related R-46 
1,4-linked polysaccharides starting the starch digestion and its transformation to 47 
oligosaccharides and monosaccharides.  48 
The lingual lipase is a triacylglycerol lipase that hydrolyzes dietary lipids on the carboxylic 49 
ester to produce diglycerols. This hydrolysis continues in the stomach by the gastric lipase, 50 
but the activity of lingual lipase has been described between pH 2 and 6.4, indicating that the 1 
lingual lipase is active from the mouth to the small intestine where the activity decreases at 2 
pH 6.9, while gastric lipase is still active in the intestine (Liao et al., 1984). 3 
Mucin lubricates oral surfaces, provides a protective barrier between underlying hard and soft 4 
tissues and the external environment, and aid in mastication, speech and swallowing. 5 
Saliva behaves as a buffer system to protect the mouth. Urea acts as a buffer present in total 6 
salivary fluid; it is a product of aminoacid and protein catabolism that causes a rapid increase 7 
in biofilm pH by releasing ammonia and carbon dioxide when hydrolyzed by bacterial 8 
ureases. 9 
In the main in vitro models, simulated saliva consists of a simplified version of this complex 10 
biological fluid, containing electrolytes (KCl, KSCN, NaH2PO4, NaSO4, NaCl and NaHCO3), 11 
urea and α-amylase (Gil-Izquierdo et al., 2002), whereas other models also uses uric acid and 12 
mucin (Versantvoort et al., 2005). Generally, the pH value used in this fluid is around 6.8.  13 
However, salivary digestion is omitted in some in vitro models, as the TIM-1 dynamic 14 
gastrointestinal model (Minekus et al., 1995), because it is considered that it does not 15 
represent great changes in matrices or components of interest. 16 
 17 
3.1.2. Gastric juices 18 
 19 
The gastric phase is activated when the acid secretion begins and finishes when the stomach 20 
contents reach the duodenum to start the intestinal phase. Gastric juice is secreted by the 21 
gastric glands of the stomach, and its production is regulated through specific neural and 22 
hormonal pathways, by the eating act and by the presence of food in the stomach. In the adult 23 
human, the stomach typically secretes about 2-3 liters of gastric juice per day. The three 24 
major constituents of gastric juice are the mucus, the enzymes and the aqueous component, 25 
the production of hydrochloric acid being a key factor as produces a significant drop in pH 26 
values (Forte, 1996). 27 
Gastric mucin is a large glycoprotein which is thought to play, together with NaHCO3 28 
secretion, a major role in the protection of the gastrointestinal tract from acid, proteases, 29 
pathogenic microorganisms, and mechanical trauma. 30 
The main enzyme in gastric juice is pepsin, although other enzymes like the gastric lipase are 31 
also present. Pepsin is actually a heterogeneous group of endoproteases responsible for the 32 
proteolytic activity of gastric juice (Forte, 1996). Gastric juice lowers the pH of the gastric 33 
content, due to secretion of hydrochloric acid. Gastric pH values have been reported between 34 
1 and 3 (Allen and Flemström, 2005; Jolliffe et al., 2009; Kong and Singh, 2009), while 35 
during digestion the pH can increase up to 7.5 (Kong and Singh, 2009). This pH change is 36 
important for the activation of pepsinogens precursors (Vertzoni et al., 2005) and to stabilize 37 
pepsin that has optimal proteolytic activity in the same pH range (i.e., pH 1-3).  38 
When gastric juice is neutralized as it passes into the duodenum, pepsin is denatured and thus 39 
eliminated from further digestive function. 40 
The lipids are emulsified and micellizated in the stomach and the small intestine, respectively 41 
(Carey et al., 1983). The acidic pH optimum for lipolysis is from 3.5 to 6.0 and lipase activity 42 
achieves a wide range of pH which allows the enzyme to act in the stomach where the 43 
postprandial pH is from 4.5 to 5.5. In the small intestine the pH range is between 5.0 and 6.5 44 
and lipase activity is proportional to the bile concentration after ingestion (Liao et al., 1984).  45 
In the in vitro models, gastric juice is often simulated only with a strong decrease of the pH, 46 
but more complete systems include gastric juices containing pepsin (Gil-Izquierdo et al., 47 
2002), and also several electrolytes (NaCl, KCl, CaCl2, NaHCO3), a lipase and bovine trypsin 48 
(Versantvoort et al., 2005). The gastric juice used in the TIM-1 dynamic gastrointestinal 49 
model (Minekus et al., 1995), one of the more complete, includes pepsin, mucin, glucose, 50 
glucuronic acid, urea, glucoseamine hydrochloride, BSA and several salts (NaCl, NaH2PO4, 1 
KCl, CaCl2·2H2O, NH4Cl and HCl). 2 
The pH value of the gastric juice during the in vitro GI simulation varies between models. In 3 
some cases the pH is a constant value, usually low (1.3-2) (Gil-Izquierdo et al., 2002; 4 
Versantvoort et al., 2004), but in other models pH values decrease during simulation from 5 
higher values (7-5) to lower values at the end (3-2), in a gradual or discontinuous way (Döll et 6 
al., 2004; Minekus et al., 1995). The gastric pH value is a crucial factor in the bioaccessibility 7 
determination as it is essential for the activity of pepsin, enzyme that can contribute to the 8 
release of hidden mycotoxins from proteins of the food matrix (Dall’Asta et al., 2009). 9 
However, some conjugated mycotoxins, as the DON-3-glucoside are resistant to acidic 10 
conditions, thus it is extremely unlikely that this compound can be hydrolyzed into DON in 11 
the stomach (Berthiller et al., 2011). 12 
 13 
3.1.3. Intestinal juices. 14 
 15 
Following gastric digestion, the stomach releases food into the duodenum through the pyloric 16 
sphincter. Duodenum receives pancreatic enzymes from the pancreas and bile from the liver 17 
and gallbladder. These fluids are important in aiding digestion and absorption. Peristalsis also 18 
aids digestion and absorption by churning up food and mixing it with intestinal secretions. 19 
The rest of the small intestine, located below the duodenum, consists of the jejunum and the 20 
ileum. These parts of the small intestine are largely responsible for the absorption of fats and 21 
other nutrients. The intestinal wall releases mucus, which lubricates the intestinal contents, 22 
and water, which helps dissolve the digested fragments. The main components of all the 23 
biological fluids implied in the intestinal digestion of food are: 24 
- The exocrine pancreatic secretions, which mainly contain pancreatic enzymes as proteases 25 
(in zymogenic form, including trypsinogen, chymotrypsinogen, procarboxypeptidase), lipases 26 
(that degrade triglycerides into fatty acids and glycerol), cholesterol esterase, phospholipase, 27 
nucleases and amylase. 28 
- The liver secretes bile and bicarbonate into the small intestine. The bile secretion contains 29 
bile salts, lecithin, cholesterol and bilirubin. 30 
- The small intestine secretes watery mucus (that protects the intestinal mucosa from auto-31 
digestion by proteases and acid) and hormones (like secretin, somastotin, motilin, 32 
cholecystokinin and the gastric inhibitory peptide). In the small intestine there are numerous 33 
"brush border" enzymes whose function is to further cleave the already-broken-down products 34 
of digestion into absorbable particles. Some of these enzymes include: sucrose, lactase, 35 
maltase and other disaccharides. 36 
- The large intestine secretes mucus (for lubrication and mechanical protection), and 37 
bicarbonate and potassium ions (for protection from bacterial acid). 38 
Given this high number of chemical compounds forming part of the intestinal secretions, it is 39 
understandable that in vitro models must simplify the components of the intestinal tract to the 40 
main components, especially those related with enzymatic properties. Thus in vitro small 41 
intestine simulation basically includes the main duodenal electrolytes (among which the 42 
calcium salts are very important), pancreatin (a mixture of several digestive enzymes 43 
produced by the exocrine cells of the pancreas: amylase, lipase and protease) and bile salts 44 
(Gil-Izquierdo et al., 2002; Minekus et al., 1995). Complementarily, some models add other 45 
components as mucin, lipases, BSA and urea (Versantvoort et al., 2005). 46 
Calcium ion (Ca2+) acts as a co-factor required for enzymatic activity at a low concentration, 47 
as 40 mM is enough to make, for example, lipolysis to increase (Brownlee et al., 2010; 48 
Kimura et al., 1982). This ion is usually added in simulated intestine digestion systems as 49 
CaCl2, at concentrations ranging from 0.3 to 22.2 g/L (see Table 1). 50 
Gastrointestinal enzymes generally have a greater resistance to irreversible denaturation, but 1 
in the different parts of the intestine of healthy subjects there can be a broad pH range, which 2 
can vary from pH 5.9 to pH 9 (Brownlee et al., 2010). pH values employed for the in vitro 3 
intestinal fluids used with mycotoxins have ranged from 6 to 8.2. 4 
Bile salts have a severe impact on bioaccessibility, as they have the capacity of surfacting and 5 
decreasing the surface tension, consequently, creating an apolar environment in the interior of 6 
bile salt micelles for hydrophobic contaminants and thereby increase their solubility (Oomen 7 
et al., 2004). 8 
 9 
3.1.4. Microbial interactions. 10 
 11 
The interaction of digestive microbiota with mycotoxins has been predominantly studied in 12 
models simulating the rumen of ruminants. Thus, in vitro metabolism of different mycotoxins 13 
(AFB1, AFG2, DON, diacetoxyscirpenol and T-2 toxin) by bacterial, protozoal and ovine 14 
ruminal fluid preparations has been determined by Westlake et al. (1989). Mobashar et al. 15 
(2012) have recently studied the contribution of the different microbial populations of rumen 16 
on OTA degradation using the in vitro Hohenheim gas incubator system. Authors have found 17 
that in contrast to the opinions in many publications, the bacterial (and not the protozoal) 18 
community played the dominant role in ruminal OTA degradation. Similarly, in vitro ruminal 19 
degradation of AFB1 has been described (Jiang et al., 2012). 20 
However, the most commonly in vitro models used for determination of bioaccessibility of 21 
mycotoxins in human or monogastric systems ignore what happen in the large intestine, as it 22 
is in the small intestine where absorption of mycotoxins occurs. Besides, simulation of the 23 
large intestine, for its implications in fermentation processes that take place on this location, 24 
necessarily involves the use of microbiota of human or animal origin, under anaerobic 25 
conditions, making more difficult the operating procedure. 26 
Laboratory systems to simulate the large intestine have been used successfully (Minekus, 27 
2005), but they generally do not combine physiological concentrations of metabolites with 28 
physiological numbers of fecal microorganisms. The TIM-2 large intestinal system developed 29 
at the TNO Nutrition and Food Research Center (The Netherlands) simulates human and 30 
monogastric large intestine, and use a complex, metabolic active microbiota of human origin. 31 
The fecal inoculum used contains a mixture of total anaerobes, facultative anaerobes and 32 
methanogenic bacteria, as well as Enterobacteriaceae, Bacteroides, Bifidobacterium and 33 
Lactobacillus. This model is kept always under anaerobic conditions by flushing with 34 
nitrogen (Minekus et al., 1999). At the moment, and to our knowledge, this system has not 35 
been used with mycotoxins, unlike what happened with its brother system, the TIM-1, which 36 
simulates the small intestine. 37 
The effect of different probiotic bacteria on the bioaccessibility of AFB1 and OTA (Kabak et 38 
al., 2009) and the main four AFs (Kabak and Ozbey, 2012b) has been studied using the in 39 
vitro model developed by Versantvoort et al. (2005), but in this case the bacteria used 40 
(different Lactobacillus and Bifidobacterium strains) were employed as mycotoxin adsorbents 41 
in a system that only simulates the stomach and small intestine. Thus no physiological 42 
interactions were expected and anaerobic conditions were not employed. 43 
 44 
3.1.5. Other factors: temperature, peristalsis and transit (incubation) time. 45 
 46 
Temperature used for in vitro bioaccessibility assays of mycotoxins always simulates the 47 
physiological temperature of the human being, so 37 ºC has been the selected temperature for 48 
all the studies. 49 
Regarding gastrointestinal movements, the mechanical action and hydrodynamic flow created 1 
by the contraction waves of the stomach muscles also play a critical role in gastric digestion. 2 
Movements in the stomach are agitation mechanics that help to mix the food with the 3 
components of gastric juice to obtain a homogeneous bolo. Stomach contractions generate a 4 
fluid flow of the gastric contents that cause a shearing effect on the food surface. Similarly, in 5 
the small intestine peristaltic waves not only move food along the intestine, but also mix the 6 
food chyme to help in the digestive process. In the in vitro models usually used with 7 
mycotoxins these physiological movements are simulated in different ways, as the use of 8 
orbital shakers (Gil-Izquierdo et al., 2002), head-over-heels rotation (Versantvoort et al., 9 
2004), movement of tubes in a water bath (Döll et al., 2004) or the employment of peristaltic 10 
valve pumps (Minekus et al., 1995). The influence of the movement system selected has not 11 
been properly evaluated in the bioaccessibility assays conducted with mycotoxins. 12 
The gastric emptying is regulated by different factors as the volume of the meal, its osmotic 13 
pressure and the caloric content of the food. Gastric emptying is also the final expression of 14 
complex hormonal interactions and digestive electrical signal driven by the neuronal net and 15 
juice secretions. The half-emptying time in healthy subjects occurred around 90 minutes (in a 16 
range from 60 to 277 minutes), although there are great differences between solid and fluid 17 
meals (Versantvoort et al., 2004). However, after a heavy meal completely emptying of the 18 
stomach can take up to 16 hours (Davenport, 1984). Incubation time in the stomach 19 
conditions usually used in in vitro models ranged from 2 to 4 hours. 20 
With regard to residence time in the small intestine, the mean transit time is of the order of 3 21 
hours (range 1 to 6 hours), 2-3 hours being the time usually employed in the in vitro models. 22 
 23 
3.2. In vitro models used in bioaccessibility or absorption studies on mycotoxins. 24 
 25 
Related to mycotoxins, one of the sequential discontinuous models most frequently used has 26 
been that developed by Gil-Izquierdo et al. (2002), a modification of a previous method 27 
described by Miller et al. (1981) to study iron bioavailability. This method, with slight 28 
modifications (Meca et al., 2012ab; Raiola et al., 2012ab), consists of two sequential steps: an 29 
initial saliva/pepsin/HCl digestion for 2h at 37 ºC to simulate the mouth and the gastric 30 
conditions, and a second digestion with bile salts/pancreatin for 2.5h at 37ºC to simulate 31 
duodenal digestion. 32 
Similarly, the method proposed by Versantvoort et al. (2004), and known as RIVM model, 33 
has been widely used. This system comprises a three-step procedure simulating digestive 34 
processes in mouth, stomach and small intestine. In each compartment digestion takes place 35 
after addition of simulated physiological juices and incubation at 37 ºC for a time relevant for 36 
the considered compartment. The system has been employed mainly to simulate human GI 37 
tract (Brandon et al., 2006; De Nijs et al., 2012; Kabak et al., 2009, 2012ab; Motta and Scott, 38 
2009; Versantvoort et al., 2004, 2005). A very similar compartmentalized approach, but 39 
simpler in terms of composition of simulated physiological juices, has been described by 40 
Gawlik-Dziki et al. (2009), and has been used for AFB1 bioaccessibility calculations (Simla 41 
et al., 2009). 42 
Döll et al. (2004) developed an in vitro model to simulate the effect of the GI tract on DON 43 
and ZEA and some potential detoxifying agents. The in vivo conditions (pH, temperature and 44 
transit time) mimic the porcine GI tract as reviewed by Dänicke et al. (1999) and Clemens et 45 
al. (1999). The system consists in a sequential incubation of the mycotoxins in (0.1 M, , pH 5) 46 
phosphate-citrate buffer during 2 h followed by a pH decrease to 3.0 using 300 µL of ortho-47 
phosphoric acid (85%), pH value that is maintained during 2 h (4 h in all, simulates gastric 48 
digestion). Thereafter, the pH is increased to 6.0 by adding 600 µL NaOH (12 M) and 49 
incubation for 3 h after adjusting the pH to 7.0 with 400 µL NaOh (12 M). All the incubations 1 
are carried out in a water bath regulated at 37 ºC. 2 
The dynamic in vitro gastrointestinal model developed at the TNO, known as TIM model has 3 
been widely used in the determination of absorption of mycotoxins and other contaminants 4 
(Minekus, 1998; Minekus et al, 1995, 1999). TIM model is a multi compartmental, 5 
continuous, dynamic, computer-controlled system which closely simulates the in vivo 6 
conditions of the stomach and small intestine (TIM-1) and large intestine (TIM-2) of humans 7 
and monogastric animals. The system simulates the peristaltic movements in the GI tract, 8 
mixing and moving the contents gradually through the stomach and the intestine. This system 9 
allows the simulation of the gastric empyting and intestinal transit times, and a computer-10 
controlled system introduces the simulated salivary, gastric, biliary and pancreatic secretions 11 
at the appropriate moment. Absorption of water and digested food compounds from the small 12 
intestinal compartment is achieved by the use of hollow fiber membrane systems that are 13 
hooked up at the middle and end part of the small intestine simulating the jejunum and ileum 14 
(Zeijdner et al., 2004). In the large intestinal model (TIM-2) a complex metabolic active 15 
microbiota of human origin performs the fermentation of undigested food components 16 
(Minekus, 2005). The system has been used simulating the human situation for babies, young 17 
adults and elderly people (Dominy et al., 2004; Minekus, 1998; Oomen et al., 2002) and, on 18 
the other hand, the dog, pig and calves situation (Avantaggiato et al., 2003, 2004, 2005, 2007; 19 
Minekus, 1998; Smeets-Peeter et al., 1998, 1999). This system seems to be one of the more 20 
complete and realistic of those available, but it has also some limitations as there are no 21 
mucosal cells inside the model, there is no immune system and there are no real feed back 22 
mechanisms, except for pH and intestinal water absorption (Zeijdner et al., 2004). 23 
Table 1 shows the main methods used to evaluate the bioaccessibility or absorption of 24 
mycotoxins, as well as their main characteristics. 25 
 26 
[Insert Table 1 in this place, if possible] 27 
 28 
4. In vitro bioaccessibility/absorption data of mycotoxins 29 
 30 
Although simulated gastric and intestinal fluids have been used extensively in the evaluation 31 
of the stability of the adsorbent-mycotoxin union (Ramos, 1996a; Scheideler, 1989), it was 32 
not until the development of the in vitro GI models described previously that effective 33 
evaluation of the bioaccessibility/absorption of mycotoxins in different food matrices has 34 
begun. In the next sections, available data on bioaccessibility or absorption of mycotoxins, 35 
calculated using the in vitro models previously explained, will be described (Tables 2 and 3). 36 
 37 
[Insert Table 2 in this place, if possible] 38 
 39 
4.1. Aflatoxins. 40 
 41 
In 2003, Zeijdner et al. using the TIM-1 GI in vitro model tested the absorption of AFB1 in an 42 
experiment designed for the evaluation of the efficacy of a natural magnesium smectite in pig 43 
GI tract. Considering only the data from the control, without adsorbent, it could be observed 44 
that in a contaminated feed with 20 µg/kg AFB1 (65% natural contamination), the amount of 45 
mycotoxin absorbed was of 47% (Zeijdner et al., 2003, 2004). This result was confirmed by 46 
Avantaggiato et al. (2007), using the same in vitro model trying to assess the efficacy of a 47 
carbon/aluminosilicate-based product on a multicontaminated feed containing AFB1, FB1, 48 
FB2, DON, ZEA and OTA, as a 46% absorption for AFB1 was observed, although the initial 49 
level of contamination was almost 10-fold higher (193 µg/kg). The AFB1 absorption occurred 50 
mainly (approx. 75%) at the upper part of the system (simulating jejunum) and less at the 1 
ileum. 2 
Shortly after, Versantvoort et al. (2004), in the first document where the term 3 
“bioaccessibility” is applied in the field of mycotoxins, described the bioaccessibility of AFB1 4 
from peanut slurries using the RIVM model for GI human tract simulation. Data obtained 5 
using a low amount of AFB1 (3 ng AFB1, from 0.5 g of a peanut slurry contaminated at 6 6 
µg/kg) or a higher amount (27 ng AFB1, from 4.5 g of a peanut slurry containing 6 µg/kg) 7 
showed similar results of bioaccessibility, ranging between 80 and 81%, considerably higher 8 
than the previous works. The bioaccessibility of AFB1 from 9 peanut slurries ranging from 0.6 9 
to 14 µg/kg in the chyme (1.5 to 36 µg/kg contamination level of peanuts) was determined 10 
and it was observed that a more or less constant bioaccessibility percentage of 90% at each 11 
contamination level was found. The bioaccessibility rose to 104-111% when AFB1 was in a 12 
food mix containing a standard meal plus the peanut slurry (1 and 3 ng AFB1 in the digestion 13 
model). To test the robustness of the digestion model, some changes were applied, as the 14 
decrease of the pH in the small intestinal compartment, the prolongation of the incubation 15 
time in the small intestine section (4h instead 2h), or doubling the bile concentration, but none 16 
of these variations affected the bioaccessibility of AFB1 from the food mix. This data were 17 
confirmed with very slight modifications (83-84% bioaccessibility in peanut slurries, 108-18 
115% in food mix) shortly thereafter by the same authors (Versantvoort et al., 2005), and by 19 
Simla et al. (2009) in ground corn (92.5-98.1% bioaccessibility) and peanut (91.2-97.0% 20 
bioaccessibility).  21 
Kabak et al. (2009), who also used the RIVM in vitro model found similar data, with an AFB1 22 
bioaccessibility that ranged from the 86% in naturally contaminated pistachio nuts, to the 88-23 
94% in artificially contaminated infant food. These authors also found that the 24 
bioaccessibility of AFB1 could be reduced in a 37% by the addition of a probiotic bacteria 25 
(Lactobacillus acidophilus NCC12). Although other probiotics were used (from Lactobacillus 26 
and Bifidobacterium genera), results were not conclusive when the standard deviations were 27 
taken into account.  28 
These authors extended their studies on AFs bioaccessibility to the four main Aflatoxins 29 
(Kabak and Ozbey, 2012) and to AFM1 (Kabak and Ozbey, 2012a). In the first case, a wide 30 
range of artificially contaminated food matrices were assayed (peanut, pistachio, hazelnut, 31 
dried figs, paprika, wheat and corn) finding bioaccessibilities that ranged from 85.1-98.1% for 32 
AFB1, 83.3-91.8% for AFB2, 85.3-95.1 for AFG1 and 80.7-91.2% for AFG2. The 33 
bioaccessibilities of all four toxins were independent of the 3 spiking levels (2, 5 and 10 34 
µg/kg for AFB1 and AFG1, and 0.6, 1.5 and 3 µg/kg for AFB2 and AFG2) and the 7 different 35 
food matrices assayed. The highest AFB1 bioaccessibility value was reported in dried figs 36 
(average 94.4%), whereas the lowest was detected in wheat samples (average 87.2%). Again, 37 
these authors studied the effect of the addition of probiotic bacteria (from Lactobacillus and 38 
Bifidobacterium genera), finding a bioaccessibility reduction that could reach in the best 39 
situation a 35.6% reduction. 40 
With regard to AFM1, results found in spiked and naturally contaminated UHT milk, with 41 
contamination levels ranging from 0.011 to 0.939 µg/L, showed bioaccessibilities around 42 
80.5-86.3% (Kabak et al., 2012a). There were no significant differences among the spiked 43 
and naturally contaminated milk samples. 44 
Assuming that the bioaccessibility of AFs, including AFM1, would be around 80-90%, 45 
depending on the matrices and contamination levels considered; it can be concluded that AFs 46 
are almost completely released from the food matrices during digestion, implying a high 47 
toxicological risk. 48 
 49 
4.2. Ochratoxin A. 50 
 1 
At present, there are few studies on the bioaccessibility of OTA and its relation to different 2 
food matrices. Versantvoort et al. (2004), using the RIVM model, determined the OTA 3 
bioaccessibility in two lots of buckwheat, finding that a considerable amount of OTA, above 4 
45%, was released from the food matrix. Bioaccessibilities seemed to be not dependent of the 5 
amount of food in the digestion model, the presence of other components in the food matrix 6 
or some variations in parameters of the in vitro model (as lowering the intestinal pH, 7 
prolongation of the transit time or doubling the bile concentration). Values obtained ranged 8 
from 45% (in a buckwheat batch contaminated at 20 µg/kg) to 84% (in a buckwheat batch 9 
contaminated at 7 µg/kg). 10 
However, in 2005, the same authors using the same experimental design reported 11 
bioaccessibilities of OTA considerably higher. Thus, values ranging from 86 to 116% were 12 
described, although in this second report the amount of mycotoxin used in the digestion 13 
model was lower (Versantvoort et al., 2005). 14 
Those data agree with the results later reported by Avantaggiato et al. (2007) who found, 15 
using the TIM-1 model with an artificially OTA contaminated corn feed, absorptions near 16 
88%. Most of the OTA was released from the food matrix in the jejunal dialysate, showing a 17 
high absorption in the upper part of the small intestine, whereas in the ileal dialysate 18 
absorption of the ingested OTA was limited to approximately 15%. 19 
However, Kabak et al. described again in 2009 much lower values for OTA bioaccessibility 20 
(22-32%) using the RIVM model with naturally OTA contaminated buckwheat or with low- 21 
and high-contaminated spiked infant foods. Bioaccessibilities found seemed not to be 22 
contamination level dependent, but it seemed that bioaccessibility increased if spiked 23 
contamination was employed, as in this case the toxin may not be tightly bound to the food 24 
matrix. Besides, the authors suggested that the difference found between the bioaccessibility 25 
of AFB1 and OTA (AFB1:OTA ratio at 3:1, according to their data) should be taken into 26 
account in risk assessment, as AFB1 presents a higher toxicological risk.  27 
It seems obvious that more data are required to more accurately assess OTA bioaccessibility. 28 
The effect that OTA contamination level, type of contamination (natural vs. spiked) and food 29 
matrix exerts in bioaccessibility must be more profoundly studied in this mycotoxin. 30 
 31 
4.3. Patulin. 32 
 33 
Raiola et al. (2012a) determined the bioaccessibility of PAT in apple juices and purees by 34 
using an in vitro model based on the sequential steps of GI digestion defined by Gil-Izquierdo 35 
et al. (2002) (gastric and duodenal digestion), pepsin, pancreatin and bile extract used were 36 
demineralised using a Chelex-100 resin, as described by Jovaní et al. (2004). Unlike the 37 
original Gil-Izquierdo method, a brief salivary digestion was added and no dialysis of the 38 
pepsin digest was carried out. Commercial PAT-free apple products were contaminated with 39 
50 µg PAT/L (juices) or 25 µg PAT/kg (purees) and digested. A higher bioaccessibility was 40 
observed in apple juices with pulp (67.3-70.9%), followed by puree samples (55.7-58.2%). 41 
Apple and pear nectar (38.9%) and clarified apple juices (25.3-28.6%) showed much lower 42 
bioaccessibilities. The authors suggested that these data should be taken into account in the 43 
risk assessment of this toxin, as high bioaccessibilities could be found in apple juices, 44 
frequently ingested by children over 3 years. 45 
Similar high PAT bioaccessibilities were found by Brandon et al. (2012) in apple products 46 
using the RIVM digestion model. The bioaccessibility of PAT was assayed using two 47 
different amounts of food per digestion tube (2.0 and 4.5 g, representing half a meal and a 48 
normal amount of dinner). Home-made apple sauce made from apples contaminated with 49 
Penicillium expansum, and spiked apple sauce and baby fruit were assayed alone or in 50 
combination with other foods as yoghurt, biscuits or a standard Dutch dinner. Level of PAT 1 
contamination ranged from 99.8 (spiked foods) to 110-485 µg/kg (naturally contaminated). 2 
Results showed that bioaccessibility was similar for the two amounts of food and that 3 
bioaccessibility values were high, ranging between 55 and 100%. 4 
 5 
[Insert Table 3 in this place, if possible] 6 
 7 
4.4. Fusarium mycotoxins. 8 
 9 
4.4.1. Zearalenone. 10 
 11 
Avantaggiato et al. (2003) using the TIM-1 model that simulates the porcine gastrointestinal 12 
tract determined the GI absorption of ZEA. Contaminated feed (820 µg ZEA/kg), containing 13 
in its composition artificially contaminated wheat, was pumped into the GI-model. Intestinal 14 
absorption of the food-released ZEA was measured analysing the dialysates at the jejunal and 15 
ileal locations of the system. A 32% absorption was observed at the jejunal+ileal 16 
compartment, although absorption occurred mainly in the jejunal part of the model (22%). 17 
Absorption at the stomach+duodenal compartment was considerably lower (4%). Authors 18 
considered that almost all the ZEA released from the food matrix during digestion was rapidly 19 
absorbed, a result consistent with the in vivo data obtained by Ramos et al. (1996b) in rats that 20 
showed a high rate of ZEA absorption through the intestinal lumen by a passive process.  21 
These results were confirmed by Zeijdner et al. (2004) using a naturally contaminated feed 22 
(100 µg ZEA/kg). Feed was digested in a TIM-1 model during six hours, obtaining again a 23 
22% of absorption in the jejunal compartment and a 10% in the ileal compartment.  24 
Avantaggiato et al. (2007) reported an absorption of 25% (16% jejunum; 9% ileum) using a 25 
naturally contaminated feed containing 1.3 mg ZEA/kg. The authors concluded that neither 26 
the level of ZEA in the feed nor the origin of contamination (natural or spiked) has an effect 27 
on the intestinal absorption of ZEA, setting an average value of 28% of the matrix-released 28 
mycotoxin. On the other hand, absorption of ZEA in the TIM-1 model was lower and slower 29 
than the observed for other mycotoxins as FBs, DON, OTA or AFB1. Consequently, ZEA 30 
absorption took place in the distal part of the small intestine, with a higher absorption in the 31 
ileum compartment compared with the rest of mycotoxins. 32 
 33 
4.4.2. Deoxynivalenol and nivalenol. 34 
 35 
Simultaneous absorption of DON and NIV was evaluated using the porcine TIM-1 model by 36 
Avantaggiato et al. (2004). A meal containing DON and NIV spiked ground wheat was 37 
employed for absorption determination. Contamination level of the meal was 560 µg DON/kg 38 
and 760 µg NIV/kg. Results showed that both toxins were simultaneously absorbed in the 39 
small intestine, DON absorption being 2.4 times higher that NIV uptake. A total absorption of 40 
51% was observed for DON, 44% of which takes place in the jejunum and the rest in the 41 
ileum compartment. On the other hand, NIV showed a 21% absorption, 18% of which 42 
corresponding to jejunum. The authors suggested that the higher absorption of DON with 43 
regard to NIV (ratio 5:2) may be due to its higher hydrophobicity. 44 
However, using the same in vitro model, higher values for DON absorption (68% at jejunum; 45 
6% at ileum) were found later using 10-fold naturally contaminated grains (Avantaggiato et 46 
al., 2007).  47 
Recently, Raiola et al. (2012b) determined the bioaccessibility of DON in pasta samples using 48 
the human in vitro model described by Gil-Izquierdo et al. (2002), slightly modified. In most 49 
of the samples, the in vitro model was adjusted to simulate child digestion (higher gastric pH, 50 
reduced amount of pepsin, pancreatin and bile salts) and in this case the mean value for DON 1 
bioaccessibility was 19.5% (ranging from 2.12% to 38.41%) for the gastric compartment and 2 
9.7% for the duodenal compartment (range 1.11-17.91%). In one sample where adult 3 
digestion was simulated, the bioaccessibilities found were considerably higher (32.81% 4 
average; 41.49% for gastric and 24.13% for duodenal compartments). Although 5 
bioaccessibilities found in the adult model were higher, authors postulate that, considering the 6 
small dimension of the child intestinal tract, the released DON present in this place could 7 
probably produce more damage to the intestinal enterocytes respect to that in an adult. 8 
Regarding masked mycotoxins, a conjugated form of DON, the DON-3-ß-D-glucoside (DON-9 
3-G) could be present in DON-contaminated plants, as glucosylation represents a major route 10 
to detoxify xenobiotics for plants. In fact, it has been proven that in some cases mean DON-3-11 
G contamination exceeded the DON contamination (Sasanya et al., 2008). A major concern is 12 
the hydrolysis of the DON-3-G conjugate back to its toxic precursor DON during 13 
gastrointestinal passage. This fact could clearly influence the real bioaccessibility value of 14 
this toxin in a food from which only DON contamination is known. For this reason DON 15 
reversion from DON-3-G was determined using an in vitro experiment that mimics the 16 
digestion conditions at the GI tract (acid hydrolysis of DON-3-G using 0.02-0.2 M HCl, pH 17 
1.7-0.7; artificial stomach juice containing pepsin; artificial non-microbial gut juice 18 
containing pancreatin) (Berthiller et al., 2011). Results showed that neither the acidic 19 
hydrolysis nor the GI enzymatic simulations resulted in DON regeneration. However, 20 
metabolic activity of some usual GI bacteria could produce the hydrolysis of DON-3-G to 21 
DON. Several Enterococcus species (E. durans, E. faecium and E. mundtii), but also 22 
Enterobacter cloacae, Lactobacillus plantarum and Bifidobacterium adolescentis were able to 23 
cleave DON-3-G in the semi-anaerobic conditions assayed, releasing up to values from 6 to 24 
62% of DON after 8h, depending of the considered species. Similarly the hydrolytic enzyme 25 
cellobiase produces a 73% DON-3-G hydrolysis in 18h, suggesting that DON- 3-G could be 26 
cleaved and DON released in the GI tract of plant-based cellulose-foraging ruminants 27 
(Berthiller et al., 2011). 28 
Once the possibility of a GI reversion of DON-3-G was stated, De Nijs et al. (2012) 29 
calculated the possible transformation of this masked mycotoxin to DON using the RIVM in 30 
vitro digestion model. Thus, an infant formula with 2778 µg DON-3-G/kg was introduced 31 
into the system, but DON was not detected in the chyme of the digested samples (this means 32 
that, in theory, less than 5% of DON-3-G was hydrolysed to DON). The level of DON-3-G 33 
detected after digestion was 55% (that is, the bioaccessible fraction). When samples were 34 
only spiked with DON (2222 µg/kg) the amount of DON detected after digestion was 65%, 35 
and DON-3-G was not detected. These results confirm the previous data, but as this model 36 
does not consider the existence of intestinal microbiota, the question of whether the DON-3-G 37 
hydrolysis at this location would lead to an increase in the DON uptake remains unanswered. 38 
 39 
4.4.3. Fumonisins. 40 
 41 
Absorption of FB1 and FB2 were determined by Avantaggiato et al. (2007) in a naturally 42 
contaminated blend of grains by using the TIM-1 in vitro model. Absorption of both 43 
mycotoxins takes place mainly in the simulated jejunum (87% FB1, 75% FB2) and in a lesser 44 
extent in the ileum (17.3% FB1, 13.9% FB2). Thus, average intestinal absorption was 104% 45 
for FB1 and 89% for FB2, indicating that release of FBs from the food matrix and, 46 
consequently, absorption in the simulated intestinal tract is an almost complete fact and that 47 
absorption of bioaccessible fumonisins would take place mainly in the upper part of the small 48 
intestine. On the other hand, maximum absorption occurred in the first 2 hours of digestion. 49 
These results do not agree with those from in vivo experiments, as it is known that FB1 has 50 
very species-specific toxicity and a very low bioavailability when administered orally, 1 
resulting from low uptake coupled with efficient biliary excretion (Shier, 2000). Low oral FB1 2 
bioavailability has been demonstrated in swine (3-6%) (Prelusky et al., 1994) and laying hens 3 
(0.7%) (Vudathala et al., 1994), whereas in cows no FB1 or known metabolites were found in 4 
the plasma of orally administered cows, indicating no or very limited bioavailability in 5 
ruminants (Prelusky et al., 1995). These discrepancies between the results obtained in vitro 6 
and highlight the limitations of in vitro models.  7 
It has been hypothesized that the totally hydrolyzed FB1 metabolite HFB1 is the real molecule 8 
involved in fumonisin toxicity, is more polar than FB1 and in vivo studies demonstrated its 9 
higher absorption in rats (Hopmans et al., 1997). However, recent in vivo studies wih piglets 10 
have shown that FB1 hydrolysis strongly reduces its toxicity both in the GI tract and the liver 11 
(Grenier et al., 2012) these findings suggest that HFB1, rather than being the molecule 12 
implicated in FB1 toxicity, represents a mechanism for detoxification. Effects of HFB1 on the 13 
intestine have been poorly studied, and most of the data have been obtained from in vitro 14 
studies with intestinal cell lines.  15 
It has been demonstrated that although HFB1 could be absorbed in a dose-dependent manner 16 
by the human colon adenocarcinoma Caco-2 cells, while FB1 was not absorbed by human 17 
colon adenocarcinoma Caco-2 monolayer of cells. In spite of this, HFB1 was not accumalated 18 
inside the cells, and no viability alterations or barrier damage was observed (De Angelis et al., 19 
2005). Similarly, in vivo HFB1 ingestion assays showed that this compound did not induce 20 
toxic effect in the piglet intestine, as intestinal integrity was not altered and intestinal 21 
immunity was not compromised (Grenier et al., 2012). 22 
Dall’Asta et al. (2009) addressed the problem created by the presence of hidden (masked) 23 
FBs in the food matrix, as we explained before regarding DON-3-G. With regard to 24 
extractable FBs (expressed as the sum of FB1, FB2 and FB3) an increase of 30-50% in FB 25 
concentration was observed after in vitro digestion of naturally contaminated corn flours 26 
using the RIVM model, which greatly affects the bioaccessibility determination. The authors 27 
suggested that the binding mechanism of FBs in raw corn is mainly due to an association with 28 
macromolecules such as starch and proteins. Additionally, no hydrolyzed or partially 29 
hydrolyzed FBs were found in the chyme. Besides, the total FBs found after digestion are 30 
slightly higher than those obtained after an alkaline hydrolysis, suggesting that masked FBs 31 
are native forms, which can be released under conditions found in the GI tract. As a clear 32 
example of how the presence of masked mycotoxins could affect bioaccessibility 33 
measurements, in a reference material with a declared FBs contamination of 3036 µg/kg, an 34 
amount of 8010 µg/kg of free FBs was detected after the in vitro digestion (Dall’Asta et al., 35 
2009). 36 
Similarly, Motta and Scott (2009) studied the bioaccessibility of total bound FB1 (TB FB1) in 37 
naturally contaminated corn flakes using the RIVM model. Corn flake samples assayed had a 38 
low level (23 µg/kg TB FB1) or high level (92 µg/kg TB FB1) of contamination. Results 39 
showed that in the case of the high level contaminated corn flakes a 51% (range 37-64%) 40 
bioaccessibility of TB FB1 was found, showing that masked mycotoxins could be 41 
bioaccessible for absorption at the small intestine. In addition, authors suggested that TB FB1 42 
could be a substrate for the intestinal bacteria and could be also hydrolyzed to regenerate the 43 
FB1 or to create other hydrolyzed metabolites, increasing the possibility of exposure to this 44 
group of toxins after ingestion. 45 
 46 
4.4.4. Emerging Fusarium mycotoxins. 47 
 48 
Fusarium species are also responsible for the production of another group of bioactive 49 
compounds considered as “minor” mycotoxins. This group includes enniatins (ENA, ENA1, 50 
ENB and ENB1), fusaproliferin and beauvericin (Meca et al., 2010). All of these toxins 1 
belong to the group of “emerging” mycotoxins, which are neither routinely determined, nor 2 
legislatively regulated; however, the evidence of their incidence is rapidly increasing. 3 
Enniatins represent an emerging food safety issue because of their extensive incidence, 4 
documented in recent decades, in various small grain cereals (Santini et al., 2012). 5 
Bioaccessibility of ENNs has been evaluated by the in vitro method of Gil-Izquierdo et al. 6 
(2002) on spiked wheat crispy breads (Meca et al., 2012a). Thus, breads were contaminated 7 
with ENA, ENA1, ENB and ENB1 at two concentrations each (1.5 and 3.0 µmol/g) and 8 
gastric and duodenal bioaccessibilities were calculated. At the gastric compartment, 9 
bioaccessibility ranged between 69.0% (ENA1 at 1.5 µmol/g) and 91.0% (ENA at 3 µmol/g), 10 
whereas at duodenal compartment the range was between 68.6% (ENB at 1.5 µmol/g) and 11 
87.3% (ENA at 3 µmol/g). The enniatin that showed the highest bioaccessibilities was the 12 
ENA, and the mean bioaccessibility considering the four compounds analyzed resulted in 13 
80%. Given the fact that cereals are frequently contaminated, that it has been demonstrated 14 
that ENs can exert toxic activity at low micromolar concentrations in mammalian cells (Meca 15 
et al., 2011), and that high bioaccessibilities were found these data must be taken into account 16 
in future legislative actions. 17 
A similar study was conducted by the same group with beauvericin (Meca et al., 2012b). BEA 18 
has also shown to be toxic in in vitro studies with human cell lines, including the intestinal 19 
Caco-2 cells (Prosperini et al., 2012). Gil-Izquierdo et al. (2002) model was used, with slight 20 
modifications; a simulation of the large intestine (colonic digestion) was employed 21 
introducing a high inoculum (1014 cfu/mL) of several characteristic bacteria of the GI tract 22 
after the duodenal digestion. Wheat crispy breads were spiked with 5 or 25 mg BEA/kg; 23 
bioaccessibility was around 40% until duodenal digestion and around 30% until 24 
duodenal+colonic digestion, with higher bioaccessibilities at the lower BEA dose employed. 25 
When crispy breads were produced with different concentrations of soluble alimentary dietary 26 
fibers, bioaccessibilities were drastically reduced at the duodenal digestion, but results were 27 
quite variable when considered the joint duodenal+colonic digestion. Thus, some fibers as 28 
chitosan medium MW and galattomannan considerably reduced BEA bioaccessibility when 29 
used at 5%. On the contrary, the use of fructooligosaccharides, inulin or pectin increases the 30 
BEA bioaccessibility after duodenal+colonic digestion, mainly at low BEA levels (5 mg/kg). 31 
 32 
5. Conclusions 33 
 34 
According to the reviewed studies, it can be concluded that bioaccessibility of mycotoxins 35 
greatly depends on the considered toxin, as well as on the food matrix in which experiments 36 
are carried out. As a general rule it can be established that bioaccessibility of AFs, FBs and 37 
ENNs shows high values, generally ranging between 70 and 100%, while PAT, DON and 38 
BEA show intermediate values, around 30-70%, and ZEA presents lower values. The 39 
bioaccessibility of OTA has proven to be very variable, with values near 100% in some cases 40 
but below 30% in others. 41 
The great variability of results between different mycotoxins and, for the same mycotoxin 42 
among the different studied matrices, highlights the need for further studies on bioaccessibility 43 
of these fungal metabolites, increasing the number and types of studied foods. The true 44 
knowledge of the percentage of mycotoxin that can be absorbed in the small intestine, from 45 
the initially present in food, would enable a more accurate risk assessment. 46 
It is also necessary to increase the number of studies with naturally contaminated foods, as the 47 
mycotoxin-matrix binding has shown to be stronger, which could affect the bioaccessibility 48 
values. On the other hand, when working with spiked samples it is necessary that the 49 
mycotoxin contamination level fits the natural contamination found in foods. In the same 50 
sense, a special attention has to be paid to masked mycotoxins, as an overestimation of 1 
bioaccessibility could occur due to an incorrect estimation of the bioaccessible toxin after the 2 
digestive process, in relation to the initially known amount of toxin. 3 
Determination of the internal exposure is a good approach to improve the risk assessment of a 4 
mycotoxin. In vitro methods offer an appealing alternative to human and animal studies. They 5 
can be rapid, simple and reasonably low in cost, can be used to perform simplified 6 
experiments under uniform and well-controlled conditions, and may provide insights not 7 
achievable in whole animal studies, but they are not free of some weaknesses. In one hand, in 8 
many cases they do not take into account important physiological factors as the lack of 9 
intestinal mucosa, enterohepatic cycling, and immune system and, in most cases they do not 10 
take into account the existence of an intestinal microbiota which possesses enzymatic 11 
capabilities that can decisively influence the release of the mycotoxin from the food matrix or 12 
the bioconversion of these toxins in the GI tract. On the other hand, these models usually do 13 
not take the large intestine into account, as absorption of toxins mainly takes place in the small 14 
intestine. 15 
Combined use of these in vitro digestion models with other techniques that employ intestinal 16 
cell lines, as in vitro intestinal absorption models that use Caco-2 cells (De Nijs et al., 2012), 17 
conducting for instance transepithelial transport studies (Meca et al., 2012a, Prosperini et al., 18 
2012) may offer a more complete picture of what happens in the intestinal tract during 19 
intestinal digestion. 20 
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